| 1 |
Cao W, Zheng J, Li Q, et al. Global, regional, and national temporal trends in prevalence, deaths and disability-adjusted life years for chronic pulmonary disease, 1990-2021: an age-period-cohort analysis based on the global burden of disease study 2021[J]. Front Med (Lausanne), 2025, 12: 1554442.
|
| 2 |
Yin P, Wu J, Wang L, et al. The Burden of COPD in China and Its Provinces: Findings From the Global Burden of Disease Study 2019 [J]. Front Public Health, 2022, 10: 859499.
|
| 3 |
丁剑，朱述阳. 慢性阻塞性肺疾病合并非酒精性脂肪肝的临床特点分析[J]. 医学综述，2019, 25(2): 412-416.
|
| 4 |
Viglino D, Plazanet A, Bailly S, et al. Impact of non-alcoholic fatty liver disease on long-term cardiovascular events and death in chronic obstructive pulmonary disease [J]. Sci Rep, 2018, 8(1): 16559.
|
| 5 |
Shaltout SW, El-Maksoud MA, Rahman AA, et al. Clinical spectrum of nonalcoholic fatty liver disease in patients with chronic obstructive pulmonary disease [J]. Turk Thorac J, 2022, 23(6): 420-425.
|
| 6 |
Zheng D, Liu X, Zeng W, et al. Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults [J]. Sci Rep, 2024, 14(1): 10822.
|
| 7 |
Pellegrini JR Jr, Munshi R, Patel P, et al. The Impact of Hepatic Cirrhosis on Chronic Obstructive Pulmonary Disease in the United States: A Nationwide Analysis [J]. Cureus, 2021, 13(7): e16368.
|
| 8 |
Polverino F, Sin DD. Type 2 airway inflammation in COPD[J]. Eur Respir J, 2024, 63(5): 2400150.
|
| 9 |
Barreby E, Chen P, Aouadi M. Macrophage functional diversity in NAFLD-more than inflammation [J]. Nat Rev Endocrinol, 2022, 18(8): 461-72.
|
| 10 |
Sakasai-Sakai A, Takeda K, Takeuchi M. Involvement of intracellular TAGE and the TAGE-RAGE-ROS axis in the onset and progression of NAFLD/NASH [J]. Antioxidants (Basel, Switzerland), 2023, 12(3): 738.
|
| 11 |
Kume H, Yamada R, Sato Y, et al. Airway smooth muscle regulated by oxidative stress in COPD [J]. Antioxidants (Basel), 2023, 12(1): 142.
|
| 12 |
Botello-Manilla AE, López-Sánchez GN, Chávez-Tapia NC, et al. Hepatic steatosis and respiratory diseases: a new panorama [J]. Ann Hepatol, 2021, 24: 100320.
|
| 13 |
Jullian-Desayes I, Trzepizur W, Boursier J, et al. Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysis [J]. Sleep Med, 2021, 77: 357-364.
|
| 14 |
阚海峰，陈龙，杨志云，等. 阻塞性睡眠呼吸暂停低通气综合征与肝纤维化关系的研究[J]. 中国全科医学，2014, 17(33): 3918-3921.
|
| 15 |
磨奕玲，周晓玲，孙东琪，等. 肝脏缺氧微环境与肝硬化发生发展关系的研究现状[J]. 中西医结合肝病杂志，2025, 35(9): 1181-1185.
|
| 16 |
Zheng J, Shi Y, Xiong L, et al. The expression of IL-6, TNF-α，and MCP-1 in respiratory viral infection in acute exacerbations of chronic obstructive pulmonary disease[J]. J Immunol Res, 2017, 2017: 8539294.
|
| 17 |
Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations [J]. Clin Chest Med, 2020, 41(3): 421-438.
|
| 18 |
Du W, Guan H, Wan X, et al. Circulating liver function markers and the risk of COPD in the UK Biobank [J]. Front Endocrinol (Lausanne), 2023, 14: 1121900.
|
| 19 |
Georgakopoulou VE, Asimakopoulou S, Cholongitas E. Pulmonary function testing in patients with liver cirrhosis (Review) [J]. Med Int (Lond), 2023, 3(4): 36.
|
| 20 |
Sadettin D, Necmiye FC, Selim GN, et al. Assessment of pulmonary functions with spirometry method in hepatic impairment patients[J]. Ann Med Res, 2021, 28(1): 106-112.
|
| 21 |
Park MS, Lee MH, Park YS, et al. Abnormal gas diffusing capacity and portosystemic shunt in patients with chronic liver disease[J]. Gastroenterology Res, 2012, 5(5): 182-189.
|
| 22 |
Vaishnav B, Barla DR, Ruchitha P, et al. Pulmonary dysfunction in patients with cirrhosis of the liver: A study of pulmonary function tests and arterial blood gases [J]. Int J Appl Basic Med Res, 2024, 14(1): 48-53.
|
| 23 |
徐纪文，徐静雅，宗斌，等. COPD并发肺部感染TLR4/NF-κB通路与细胞因子水平及意义[J/OL]. 中华肺部疾病杂志(电子版), 2022, 15(2): 221-223.
|
| 24 |
张林，徐厚平，刘代群，等. 黄芩素调控TLR4/NF-κB通路对慢性阻塞性肺疾病大鼠气道炎症的影响[J]. 中国免疫学杂志，2025, 41(4): 903-907.
|
| 25 |
何腾飞，张安妮，张常喜. 补肺纳肾丸调控PI3K/AKT信号通路介导的MMP/TIMP平衡减轻慢性阻塞性肺疾病细胞外基质沉积的作用机制[J]. 中国中药杂志，2026, 51(8): 2335-2348.
|
| 26 |
Deng M, Scott MJ, Loughran P, et al. Lipopolysaccharide clearance，bacterial clearance, and systemic inflammatory responses are regulated by cell type-specific functions of TLR4 during sepsis[J]. J Immunol, 2013, 190(10): 5152-5160.
|
| 27 |
Liu Y, Nong L, Jia Y, et al. Aspirin alleviates hepatic fibrosis by suppressing hepatic stellate cells activation via the TLR4/NF-κB pathway[J]. Aging (Albany NY), 2020, 12(7): 6058-6066.
|
| 28 |
朱呈辉，李骏飞，姜建伟. 消瘰丸通过抑制PI3K/Akt信号通路发挥抗肝纤维化作用：基于网络药理学和动物实验[J]. 广东医科大学学报，2025, 43(5): 530-539.
|
| 29 |
孟蕾，谢波. 慢性阻塞性肺疾病患者的氧化应激改变及其诊断分析[J]. 贵州医药，2023, 47(12): 1863-1865.
|
| 30 |
张铭，柴沛. 慢性阻塞性肺疾病急性加重患者血清Notch1、Caspase-3、ROS水平与病情严重程度及预后的关系[J]. 分子诊断与治疗杂志，2024, 16(10): 1957-1960，1969.
|
| 31 |
Hunt AN, Malur A, Monfort T, et al. Hepatic steatosis accompanies pulmonary alveolar proteinosis[J]. Am J Respir Cell Mol Biol, 2017, 57(4): 448-458.
|
| 32 |
Yazdani R, Fallah H, Yazdani S, et al. Effect of plasma free fatty acids on lung function in male COPD patients[J]. Sci Rep, 2025, 15(1): 3377.
|
| 33 |
Okada A, Sera S, Taguchi M, et al. Current status and usefulness of therapeutic drug monitoring implementation of theophylline in elderly patients based on a nationwide database study and modeling approach [J]. Sci Prog, 2024, 107(3): 368504241285122.
|
| 34 |
Papadopoulou E, Bin Safar S, Khalil A, et al. Inhaled versus systemic corticosteroids for acute exacerbations of COPD: a systematic review and meta-analysis[J]. Eur Respir Rev, 2024, 33(171): 230151.
|
| 35 |
Yong S H, Leem AY, Kim YS, et al. Hepatic fibrosis assessed using fibrosis-4 index is predictive of all-cause mortality in patients with chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 831-839.
|
| 36 |
Ferreira I, Gouveia C, Vasques CSR, et al. Drug-induced liver injury caused by amoxicillin/clavulanate[J]. Cureus, 2020, 12(12): e12234.
|
| 37 |
Zhang ZY, Li YH. Effects of different exercise regimens on prognosis of patients with chronic obstructive pulmonary disease: a systematic reviews and meta-analysis[J]. Ann Med, 2024, 56(1): 2392022.
|
| 38 |
Oyama Y, Tatsumi H, Takikawa H, et al. Combined effect of early nutrition therapy and rehabilitation for patients with chronic obstructive pulmonary disease exacerbation: a prospective randomized controlled trial[J]. Nutrients, 2024, 16(5): 739.
|
| 39 |
Russo C, Valle MS, Casabona A, et al. Vitamin d impacts on skeletal muscle dysfunction in patients with COPD promoting mitochondrial health[J]. Biomedicines, 2022, 10(4): 898.
|
| 40 |
Baek EB, Eun HS, Song JY, et al. Vitamin D supplementation ameliorates ductular reaction, liver inflammation and fibrosis in mice by upregulating TXNIP in ductular cells[J]. Nat Commun, 2025, 16(1): 4420.
|
| 41 |
Ciardullo S, Muraca E, Cannistraci R, et al. Low 25 (OH) vitamin D levels are associated with increased prevalence of nonalcoholic fatty liver disease and significant liver fibrosis [J]. Diabetes Metab Res Rev, 2023, 39(5): e3628.
|
| 42 |
王佳怡，胡笛，潘江，等. 温针灸联合低强度抗阻运动训练治疗慢性阻塞性肺疾病的疗效观察[J]. 上海针灸杂志，2025, 44(8): 930-935.
|
| 43 |
尹巧英，王石榴，何希芝，等. 针药结合治疗非酒精性脂肪性肝炎的疗效观察[J/OL]. 中华针灸电子杂志，2022, 11(4): 133-136.
|